维拉帕米对心肌细胞肥大的影响

目的研究维拉帕米对心肌细胞肥大的影响及其机制。方法测定培养的心肌细胞［Ｃａ２＋］ｉ和３Ｈ－亮氨酸（３Ｈ－Ｌｅｕ）参入。结果２×１０－７ｍｏｌ／Ｌ维拉帕米对培养的心肌细胞［Ｃａ２＋］ｉ和３Ｈ－Ｌｅｕ参入无明显影响（Ｐ＞０．０５），２×１０－６～１０－５ｍｏｌ／Ｌ维拉帕米则可显著抑制培养的心肌细胞［Ｃａ２＋］ｉ和３Ｈ－Ｌｅｕ参入。与对照组相比，心肌细胞［Ｃａ２＋］ｉ和３Ｈ－Ｌｅｕ参入分别减低１０％～２７％（Ｐ＜０．０１）和１２％～２５％（Ｐ＜０．０５）。结论维拉帕米可以抑制培养的心肌细胞肥大，作用机制可能与其降低细胞内游离钙和细胞收缩性有关。     

血小板衍生生长因子和钙拮抗剂对大鼠肝细胞胶原合成及细胞内游离钙浓度的影响

目的：观察血小板衍生生长因子（Ｐｌａｔｅｌｅｔ－ｄｅｒｉｖｄｅｇｒｏｗｔｈｆａｃｔｏｒ，ＰＤＧＦ）和钙拮抗剂（（Ｃａｌｃｉｕｍａｎｔａｇｏｎｉｓｔ，Ｃａ－Ａ）对原代培养大鼠肝细胞胶原合成以及细胞内游离钙浓度（［Ｃａ２＋］ｉ）的影响。方法：应用３Ｈ－脯氨酸掺入率法和Ｆｕｒａ－２／ＡＭ荧光示踪法分别测定细胞内胶原含量及［Ｃａ２＋］ｉ。结果：ＰＤＧＦ能促进细胞内胶原合成，提高肝内［Ｃａ２＋］ｉ，且与浓度呈正相关，而Ｃａ－Ａ具有反作用。结论：ＰＤＧＦ参与肝纤维化的形成，Ｃａ－Ａ对纤维化肝脏具有保护作用     

莲心碱对自发性高血压大鼠血管平滑肌细胞增殖及对PDGF—B,bFGF,c …

用［＾３Ｈ］胸腺嘧啶核苷（［＾３Ｈ］ＴｄＲ）掺入法、电镜、免疫组化和原位杂交方法，在自发性高血压大鼠（ＳＨＲ）观察了莲心碱（Ｌｉｌｅｎ）对血管平滑肌细胞（ＶＳＭＣ）增殖的作用及对生长因子ＰＤＧＦ－Ｂ、ｂＦＧＦ及其相关癌基因ｃ－ｓｉｓ和ｃ－ｍｙｃ表达的影响。结果发现Ｌｉｅｎ在降低ＳＨＲ血压同时，能减少ＶＳＭＣ的线粒体，粗面内质网和［＾３Ｈ］ＴｄＲ掺入量，并能逆转ＶＳＭＣ增殖对ＰＤＧＦ０Ｂ、ｂＦＧＦ抗     

组织胺通过H2受体抑制前列腺素E2刺激家兔十二指肠碳酸氢的分泌

十二指肠粘膜分泌的碳酸氢（ＨＣＯ３）是重要的“防御因子”之一。前列腺素Ｅ２（ＰＧＥ２）强烈刺激十二指肠ＨＣＯ３的分泌。本实验示，组织胺可抑制家兔近端十二指肠由ＰＧＥ２刺激引起的ＨＣＯ３－分泌（从０．４０±０．０３至０．０８±０．０ｌμｏｌ／ｃｍ２·ｈ，Ｐ＜０．０１）。此抑制作用可被神经毒素（ＴＴＸ）及Ｈ２受体拮抗剂一西咪替丁阻断（分别为０．３７±０．０６，０．４４±０．０２μｍｏｌ／ｃｍ２·ｈ），但不能被Ｈ１及Ｈ３受体拮抗剂所阻断。提示十二指肠肥大细胞、组织胺参与其ＨＣＯ３－分泌的调节，具体环节可能通过十二指肠神经丛的Ｈ２受体。     

家兔十二指肠粘膜碳酸氢盐分泌机理的研究

本实验旨在探讨ＨＣＯ３－分泌的调节及其转运的离子通道。取大白兔近端十二指肠，置于尤氏小室间（ＵｓｓｉｎｇＣｈａｍｂｅｒ），测定血管活血肠肽（ＶＩＰ）、前列腺素Ｅ２（ＰＧＥ２），二丁酰环磷腺甙（ｄｂ－ｃＡＭＰ）及电刺激（ＥＦＳ）对碳酸氢盐（ＨＣＯ３－）分泌量、电流（Ｉｓｃ）和电位差（ＰＤ）的影响，以及缺氧、缺氯、缺钠和加入ＤＩＤＳ（４，４－ｄｉｉｓｏｔｈｉｏｃｙａｎｏｓｔｉｌｂｅｎｅ－２，２’－ｄｉｓｕｌｆｏｎｉｃａｃｉｄ）、哇巴因（Ｏｕａｂａｉｎ）和神经毒素（Ｔｅｔｒｏｄｏｔｏｘｉｎ，ＴＴｘ）后对上述指标的影响。结果示，ＶＩＰ、ＰＧＥ２、ｄｂ－ｃＡＭＰ和ＥＦＳ均刺激ＨＣＯ３－分泌和Ｉｓｃ、ＰＤ的升高，而缺氧、缺钠和哇巴因呈抑制作用。ＤＩＤＳ和缺氯则完全抑制由ＰＧＥ２引起的刺激作用，部分抑制（５０％）由ＶＩＰ的刺激作用，而对ｄｂ－ｃＡＭＰ则无抑制作用。ＴＴＸ抑制由ＥＦＳ引起的作用。ＨＣＯ３－分泌与ＶＩＰ、ＰＧＥ２及ｄｂ－ｃＡＭＰ引起的细胞内ｃＡＭＰ水平不成正相关。     

MAGE-1基因在肝细胞性肝癌中的表达

目的探讨ＭＡＧＥ－１基因编码的肿瘤相关抗原作为肝细胞性肝癌（ＨＣＣ）主动免疫治疗攻击靶点的可能性。方法用ＲＴ－ＰＣＲ的方法检测了３９例ＨＣＣ及癌旁组织、３种人肝癌细胞株和５例非ＨＣＣ病例肝组织中ＭＡＧＥ－１基因的表达。结果ＨＣＣ癌组织中ＭＡＧＥ－１基因表达率明显高于癌分组织中的表达率,５８．９％（２／３９）对１０．３％（４／３９）,Ｐ＜００１。３种细胞株均为阳性表达。结论ＭＡＧＥ－１基因可作为主动免疫治疗的攻击靶点,以进一步研究设计新的ＨＣＣ免疫治疗策略。     

非肥胖高血压病患者的胰岛素抵抗及西拉普利对其影响

对３０例非肥胖高血压病（ＥＨ）患者、１７例正常血压者（ＮＴ）行口服葡萄糖耐量试验（ＯＧＴＴ）和胰岛素释放试验（ＩＲＴ）．结果显示：ＥＨ组空腹、服糖后２小时血清胰岛素及胰岛素释放曲线下面积（［ＡＵＣ］１）高于ＮＴ组；ＥＨ组空腹、服糖后２小时血糖及葡萄糖耐量曲线下面积（［ＡＵＣ］Ｇ）亦高于ＮＴ组，提示非肥胖ＥＨ患者存在胰岛素抵抗（ＩＲ）。西拉普利（ｃｉｌａｚａｐｒｉｌ）治疗后ＥＨ患者血清胰岛素、［ＡＵＣ］１、血糖及［ＡＵＣ］Ｇ均较治疗前降低，显示有改善ＩＲ的作用。     

Ge－132治疗慢性肝炎的研究结果

Ｇｅ－１３２治疗慢性肝炎的研究结果李贺成，宋祥芳Ｇｅ－１３２［（ＧｅＣＨ２ＣＨ２ＣＯＯＨ）２Ｏ３］，具有多种生物活性，为治疗慢性肝炎的有机锗药品（Ｓｅｒｏｓｉｏｎ）。用半乳糖胺、钙离子载体Ａ２３１８７、氢化氧化枯烯和异硫氰酸萘对大鼠肝细胞诱发肝损伤，...     

原发性高血压伴左心室肥厚病人的胰岛素抵抗和红细胞内钙离子代谢

目的比较原发性高血压（ＥＨ）伴左心室肥厚（ＬＶＨ）和无ＬＶＨ病人各３０例的胰岛素抵抗（ＩＲ）和细胞内游离钙浓度（［Ｃａ２＋］ｉ）的变化。用口服葡萄糖前后血浆胰岛素浓度（Ｉ）和Ｉ与血糖（Ｇ）比值来判断ＩＲ。用Ｆｕｒａ－２荧光染料测定红细胞内Ｃａ２＋。结果（１）ＬＶＨ糖负荷后的Ｉ及Ｉ／Ｇ均显著高于ＬＶＨ（－）；（２）ＬＶＨ的红细胞内Ｃａ２＋在空腹和糖负荷后均显著高于ＬＶＨ（－）；（３）ＬＶＨ的左心室重量指数（ＬＶＭＩ）与Ｉ及Ｉ／Ｇ呈正相关，ＬＶＨ（－）的ＬＶＭＩ仅与糖负荷后１ｈ的Ｉ及Ｉ／Ｇ正相关，ＬＶＨ和ＬＶＨ（－）两组的ＬＶＭＩ与红细胞内Ｃａ２＋正相关。结论ＥＨ病人伴ＬＶＨ时ＩＲ和红细胞内Ｃａ２＋增加。     

38例高血压病患者血脂与胰岛素抵抗

对３８例高血压病（ＥＨ）患者及２４例正常人空腹血清胰岛素（Ｉｎｓ）、Ｃ肽（ＣＰ）、血糖（ＳＧ）、甘油三酯（ＴＧ）、总胆固醇（ＴＣ）、高密度脂蛋白胆固醇（ＨＤＬ－Ｃ）及载脂蛋白（Ａｐｏ）含量进行测定，并推算胰岛素敏感指数（ＩＳＩ）。结果ＥＨ组Ｉｎｓ、ＣＰ升高，但ＩＳＩ显著降低，表明ＥＨ患者存在胰岛素抵抗（ＩＲ）。同时伴有ＴＧ、ＴＣ、ＡｐｏＢ１００、脂蛋白（ａ）［ＬＰ（ａ）］升高，ＨＤＬ－Ｃ、ＡｐｏＡＩ降低。相关分析表明，ＥＨ患者Ｉｎｓ与ＴＧ、ＡｐｏＢ１００、ＬＰ（ａ）呈显著正相关，与ＨＤＬ－Ｃ、ＡｐｏＡＩ呈显著负相关。ＩＳＩ与ＴＧ、ＡｐｏＢ１００呈显著负相关，提示ＥＨ患者ＩＲ可能是影响脂代谢的重要因素之一。     

Cost-effectiveness of combined interferon and ribavirin versus interferon alone

Several decision analysis, computer-generated models developed to study the cost effectiveness of current treatment for chronic hepatitis C appear to have produced similar results. They indicate that IFN monotherapy and the combination of IFN plus ribavirin treatment have calculated cost-effectiveness ratios that either fall within the bounds of other widely accepted current therapies in medicine or are cost-saving. This cost effectiveness has been shown for the treatment of previously untreated patients, for the re-treatment of patients who experience relapse after an initial course of IFN monotherapy, and for the re-treatment of those patients who did not respond to IFN monotherapy. Although targeting treatment to patients most likely to respond will improve cost effectiveness, the benefits of treatment are such that even empiric IFN monotherapy, without liver biopsy, HCV RNA quantitation, or HCV genotyping, has an acceptable cost effectiveness. Although not studied, empiric combination therapy might result in even further cost efficiencies.     

聚乙二醇干扰素治疗慢性乙型肝炎患者血清干扰素浓度及其抗体水平的变化

目的探讨聚乙二醇干扰素α2a治疗慢性乙型肝炎(CHB)患者血清干扰素浓度和干扰素抗体水平的变化,以及其对疗效的影响。方法 41例CHB患者皮下注射聚乙二醇干扰素α2a(派罗欣,罗氏公司)180μg,每周1次,在0、4、12、24和48周时用ELISA法检测干扰素浓度和干扰素抗体水平,并在停药后24周检测干扰素浓度。结果干扰素浓度在0、4、12、24、48周和停药24周时分别为22.9(3.1～45.8)pg/mL、2734(9.2～4224)pg/mL、4025(269～4462)pg/mL、3884(14.5～4567)pg/mL、3978(76.9～5227)pg/mL和62.1(52.3～74.6)pg/mL。干扰素浓度在4、12、24、48周和停药24周与0周相比,差异有统计学意义(t=9.481,P<0.01;Z=-6.862,P<0.01;Z=-6.969,P<0.01;Z=-6.477,P<0.01;Z=-4.204,P<0.01);12、24与4周相比,差异有统计学意义(Z=-4.316,P<0.01;Z=-3.830,P=0.0001);24周与12周相比,差异无统计学意义(Z=0.367,P=0.7136)。干扰素抗体水平在4、12、24、48与0周相比,差异无统计学意义(Z=-1.035,P=0.3007;Z=0.101,P=0.9192;Z=0.158,P=0.8748;Z=1.779,P=0.0752)。结论聚乙二醇干扰素α2a治疗过程中,患者血清干扰素浓度在12周达到稳定浓度,停药24周血清干扰素浓度仍略高于治疗前,而干扰素抗体浓度变化不大,二者无明显相关性。     

Age-related decline of human interferon alpha and interferon gamma production

Summary The influence of donor age on the production of interferon (IFN) alpha and IFN gamma by human peripheral blood mononuclear cells in vitro has been studied. The results demonstrate an age-related decline of the capacity to synthesize and secrete antiviral activity. Yields of virus-induced IFN alpha and lectin-induced IFN gamma were significantly decreased in mononuclear cell cultures from older subjects (> 50 years) when compared to those of younger subjects (< 50 years). The observed deficiency of IFN production may be involved in the increased susceptibility of aged humans to viral infections and malignant diseases.     

Uncommon side-effects of interferon

Summary. Beside the clinical manifestations usually observed during the treatment of chronic viral hepatitis with interferon, a small number of side-effects, less frequent and sometimes unexpected, have been described. These neurological, pulmonary, metabolic, cardio-vascular or psychiatric manifestations are uncommon but potentially severe. We here describe three cases of stroke that occured during treatment with interferon in which the role played by the molecule could be questioned.     

Beta interferon and thyroid

We report the case of a thyroiditis in a 44-year-old woman with relapsing-remitting multiple sclerosis treated with interferon beta. Before treatment, thyroid function tests were normal and anti-thyroid (anti-thyroglobulin and anti-thyroid peroxidase) antibodies were negative. After 18 months of treatment, the patient presented clinical features of thyroiditis. We noted a rise in TSH values and anti-thyroid antibodies were found positive. Treatment was not discontinued and further surveillance showed an improvement in clinical and biological features. We conclude that thyroid function should be monitored during INF beta treatment. Laboratory tests must be carried out before therapy. Clinical follow-up is indicated before undertaking biological tests.